A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naive prostate cancer.

ABSTRACT:

Introduction

The aim of this prospective phase II study was to evaluate the efficacy and safety of biweekly docetaxel plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC).

Patients and methods

Patients with histologically-proven, previously-untreated mCNPC received ADT plus docetaxel, 40 mg/m². Docetaxel was repeated every 2 weeks, up to 12 cycles. Endpoints included castration-resistant prostate cancer (CRPC)-free survival, prostate-specific antigen (PSA) response, and safety.

Results

A total of 42 patients were registered and analyzed for final outcomes. Of the 42 patients, 36 (86%) completed the 12 planned cycles of docetaxel plus ADT. During a median follow up of 25 months, all but two patients (95

SUBMITTER: Byeon S 

PROVIDER: S-EPMC8628395 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature